Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balance at the beginning (in shares) at Dec. 31, 2022   145,204,974      
Balance at the beginning at Dec. 31, 2022 $ 226,985 $ 15 $ 419,190 $ (10) $ (192,210)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon net exercise of stock options (in shares)   100,587      
Issuance of common stock upon net exercise of stock options 33   33    
Issuance of common stock upon vesting of restricted stock units (in shares)   1,841,257      
Issuance of common stock upon exercise of warrants (in shares)   830,216      
Issuance of common stock upon exercise of warrants 348   348    
Stock-based compensation cost 5,101   5,101    
Cumulative translation adjustment (16)     (16)  
Net (loss) income (28,609)       (28,609)
Balance at the end (in shares) at Mar. 31, 2023   147,977,034      
Balance at the end at Mar. 31, 2023 203,842 $ 15 424,672 (26) (220,819)
Balance at the beginning (in shares) at Dec. 31, 2022   145,204,974      
Balance at the beginning at Dec. 31, 2022 226,985 $ 15 419,190 (10) (192,210)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Cumulative translation adjustment (33)        
Net (loss) income (95,363)        
Balance at the end (in shares) at Jun. 30, 2023   149,790,742      
Balance at the end at Jun. 30, 2023 144,158 $ 15 431,759 (43) (287,573)
Balance at the beginning (in shares) at Mar. 31, 2023   147,977,034      
Balance at the beginning at Mar. 31, 2023 203,842 $ 15 424,672 (26) (220,819)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon net exercise of stock options (in shares)   775,193      
Issuance of common stock upon net exercise of stock options 310   310    
Issuance of common stock upon vesting of restricted stock units (in shares)   1,038,415      
Issuance of common stock upon exercise of warrants (in shares)   100      
Issuance of common stock upon exercise of warrants 1   1    
Stock-based compensation cost 6,776   6,776    
Cumulative translation adjustment (17)     (17)  
Net (loss) income (66,754)       (66,754)
Balance at the end (in shares) at Jun. 30, 2023   149,790,742      
Balance at the end at Jun. 30, 2023 144,158 $ 15 431,759 (43) (287,573)
Balance at the beginning (in shares) at Dec. 31, 2023   151,310,080      
Balance at the beginning at Dec. 31, 2023 146,323 $ 15 444,825 (53) (298,464)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon net exercise of stock options (in shares)   519,089      
Issuance of common stock upon net exercise of stock options 302 $ 1 301    
Issuance of common stock upon vesting of restricted stock units (in shares)   3,527,778      
Stock-based compensation cost 6,605   6,605    
Cumulative translation adjustment 3     3  
Net (loss) income (11,644)       (11,644)
Balance at the end (in shares) at Mar. 31, 2024   155,356,947      
Balance at the end at Mar. 31, 2024 141,589 $ 16 451,731 (50) (310,108)
Balance at the beginning (in shares) at Dec. 31, 2023   151,310,080      
Balance at the beginning at Dec. 31, 2023 $ 146,323 $ 15 444,825 (53) (298,464)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon net exercise of stock options (in shares) 1,342,136        
Cumulative translation adjustment $ 11        
Net (loss) income (8,182)        
Balance at the end (in shares) at Jun. 30, 2024   157,474,122      
Balance at the end at Jun. 30, 2024 153,073 $ 16 459,745 (42) (306,646)
Balance at the beginning (in shares) at Mar. 31, 2024   155,356,947      
Balance at the beginning at Mar. 31, 2024 141,589 $ 16 451,731 (50) (310,108)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon net exercise of stock options (in shares)   823,047      
Issuance of common stock upon net exercise of stock options 335   335    
Issuance of common stock upon vesting of restricted stock units (in shares)   1,294,128      
Stock-based compensation cost 7,679   7,679    
Cumulative translation adjustment 8     8  
Net (loss) income 3,462       3,462
Balance at the end (in shares) at Jun. 30, 2024   157,474,122      
Balance at the end at Jun. 30, 2024 $ 153,073 $ 16 $ 459,745 $ (42) $ (306,646)